. 2022 Jan 10;14(2):324. doi: 10.3390/cancers14020324

Table 3.

Univariate analysis of overall survival.

Variables	Number (%)	Kaplan–Meier Median OS (Months, 95%CI)	p-Value (Log-Rank)	Cox Proportional Hazards Hazard Ratio (95%CI)	p-Value (Cox)
RECIST response 3 months
DC PD	22 (62.8%) 8 (22.8%)	22 (10.9–33.1) 10 (0.0–21.9)	0.053	0.41 (0.16–1.1)	0.065
DC PD	22 (62.8%) 8 (22.8%)	22 (10.9–33.1) 10 (0.0–21.9)	0.053		0.065
RECIST response 6 months
DC PD	16 (45.7%) 9 (25.7%)	40 (17.6–62.4) 17 (8.1–25.9)	0.007	0.25 (0.08–0.75)	0.013
DC PD	16 (45.7%) 9 (25.7%)	40 (17.6–62.4) 17 (8.1–25.9)	0.007		0.013
RECIST response 9 months
DC PD	6 (17.1%) 9 (25.7%)	94 (0.0–242.1) 37 (26.7–47.3)	0.290	0.47 (0.1–1.9)	0.299
DC PD	6 (17.1%) 9 (25.7%)	94 (0.0–242.1) 37 (26.7–47.3)	0.290		0.299
Liver PFS
$\geq$ 9 months $<$ 9 months	13 (37.1%) 22 (62.9%)	50 (30.8–69.1) 8 (5.0–10.9)	<0.0001	0.14 (0.04–0.4)	<0.0001
$\geq$ 9 months $<$ 9 months	13 (37.1%) 22 (62.9%)	50 (30.8–69.1) 8 (5.0–10.9)
TACE post-TARE
Yes No	6 (17.1%) 29 (82.9%)	99 (90.9–107.0) 16 (4.9–27.0)	0.003	0.14 (0.03–0.6)	0.009
Yes No	6 (17.1%) 29 (82.9%)	99 (90.9–107.0) 16 (4.9–27.0)	0.003		0.009
Repeat TARE
Yes No	5 (14.3%) 30 (85.7%)	33 (3.7–30.3) 17 (4.9–27.0)	0.517	0.73 (0.3–1.9)	0.524
Yes No	5 (14.3%) 30 (85.7%)	33 (3.7–30.3) 17 (4.9–27.0)	0.517		0.524
Primary Metastases
Yes No	16 (45.7%) 19 (54.3%)	17 (11.1–22.9) 22 (0.0–57.5)	0.173	1.8 (0.8–4.1)	0.185
Yes No	16 (45.7%) 19 (54.3%)	17 (11.1–22.9) 22 (0.0–57.5)	0.173		0.185
Extrahepatic Metastases
Yes No	22 (62.8%) 13 (37.2%)	17 (1.6–32.4) 37 (4.6–69.4)	0.186	1.7 (0.8–3.8)	0.197
Yes No	22 (62.8%) 13 (37.2%)	17 (1.6–32.4) 37 (4.6–69.4)	0.186		0.197
Liver Involvement
Bilobar Single lobe	29 (82.8%) 6 (17.1%)	22 (7.9–35.6) 16 (0.0–35.6)	0.348	0.6 (0.2–1.7)	0.359
Bilobar Single lobe	29 (82.8%) 6 (17.1%)	22 (7.9–35.6) 16 (0.0–35.6)	0.348		0.359
Baseline Liver Volume
$>$ 1.5 L $\leq$ 1.5 L	25 (71.4%) 10 (28.6%)	17 (2.0–32.0) 20 (0.0–49.3)	0.474	1.3 (0.6–3.0)	0.481
$>$ 1.5 L $\leq$ 1.5 L	25 (71.4%) 10 (28.6%)	17 (2.0–32.0) 20 (0.0–49.3)	0.474		0.481
Child-Turcotte-Pugh Class
B A	8 (22.9%) 27 (77.1%)	6 (4.7–7.3) 22 (13.1–30.9)	0.018	2.6 (1.1–6.2)	0.025
B A	8 (22.9%) 27 (77.1%)	6 (4.7–7.3) 22 (13.1–30.9)	0.018		0.025
Baseline MELD
$>$ 9 $\leq$ 9	8 (22.9%) 27 (77.1%)	33 (0.0–91.1) 17 (11.2–22.8)	0.668	1.2 (0.5–2.9)	0.673
$>$ 9 $\leq$ 9	8 (22.9%) 27 (77.1%)	33 (0.0–91.1) 17 (11.2–22.8)	0.668		0.673
Baseline ALBI grade
Grade 2–3 Grade 1	22 (62.9%) 13 (37.1%)	16 (2.6–29.4) 33 (10.4–55.6)	0.308	1.5 (0.7–3.4)	0.318
Grade 2–3 Grade 1	22 (62.9%) 13 (37.1%)	16 (2.6–29.4) 33 (10.4–55.6)	0.308		0.318
Chemotherapy Post-TARE
Yes No	22 (62.9%) 13 (37.1%)	17 (1.9–32.1) 22 (13.7–30.3)	0.773	1.1 (0.5–2.4)	0.776
Yes No	22 (62.9%) 13 (37.1%)	17 (1.9–32.1) 22 (13.7–30.3)	0.773		0.776
Chemotherapy Pre-TARE
Yes No	27 (77.1%) 8 (22.9%)	17 (3.1–30.9) 33 (9.6–56.4)	0.619	1.2 (0.5–3.2)	0.624
Yes No	27 (77.1%) 8 (22.9%)	17 (3.1–30.9) 33 (9.6–56.4)	0.619		0.624
Liver Surgery Pre-TARE
Yes No	9 (25.7%) 26 (74.3%)	20 (11.2–28.8) 22 (3.3–40.7)	0.851	0.92 (0.41–2.1)	0.853
Yes No	9 (25.7%) 26 (74.3%)	20 (11.2–28.8) 22 (3.3–40.7)	0.851		0.853
Radiotherapy Pre-TARE
Yes No	16 (45.7%) 19 (54.3%)	8 (6.1–9.9) 25 (3.5–46.5)	0.244	1.5 (0.73–3.3)	0.254
Yes No	16 (45.7%) 19 (54.3%)	8 (6.1–9.9) 25 (3.5–46.5)	0.244		0.254
Liver-directed therapy Pre-TARE
Yes No	3 (8.6%) 32 (91.4%)	37 (3.4–70.6) 20 (8.7–31.3)	0.598	0.68 (0.16–2.9)	0.606
Yes No	3 (8.6%) 32 (91.4%)	37 (3.4–70.6) 20 (8.7–31.3)	0.598		0.606
Type of Y90 Microspheres
Resin (SIR) Glass (Theraspheres)	31 (88.6%) 4 (11.4%)	20 (13.0–26.9) 17 (0.0–46.4)	0.631	0.77 (0.3–2.3)	0.637
Resin (SIR) Glass (Theraspheres)	31 (88.6%) 4 (11.4%)	20 (13.0–26.9) 17 (0.0–46.4)	0.631		0.637
TARE Distribution
Bilobar Single Lobe/Segmental	22 (62.8%) 13 (37.2%)	22 (10.9–33.1) 16 (0.5–31.6)	0.181	0.57 (0.25–1.3)	0.193
Bilobar Single Lobe/Segmental	22 (62.8%) 13 (37.2%)	22 (10.9–33.1) 16 (0.5–31.6)	0.181		0.193
Baseline ECOG
2 0–1	6 (17.2%) 29 (82.8%)	6 (0.0–12.3) 22 (14.2–29.8)	0.042	2.7 (0.9–7.2)	0.054
2 0–1	6 (17.2%) 29 (82.8%)	6 (0.0–12.3) 22 (14.2–29.8)	0.042		0.054
Histotype
Leiomyosarcoma Other	20 (57.1%) 15 (42.9%)	20 (8.1–31.9) 16 (0.0–53.6)	0.405	0.71 (0.3–1.6)	0.413
Leiomyosarcoma Other	20 (57.1%) 15 (42.9%)	20 (8.1–31.9) 16 (0.0–53.6)	0.405		0.413

ECOG, Eastern Cooperative Oncology Groups; ALBI, albumin–bilirubin; MELD, Model for End-Stage Liver Disease; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; DC, disease control; PD, disease progression; TARE, trans-arterial radioembolization; Y90, Yttrium-90; TACE, trans-arterial chemioembolization; 95%CI, 95% confidence interval.